Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects

Mayo Clinic

Status

Enrolling

Conditions

Monoclonal B-Cell Lymphocytosis

Chronic Lymphocytic Leukemia

Treatments

Other: Non-Interventional Study

Study type

Observational

Funder types

Other

Identifiers

NCT06536452

NCI-2024-00996 (Registry Identifier)

16-006204 (Other Identifier)

Details and patient eligibility

About

This study evaluates hematopoiesis to determine how MBL/CLL affected bone marrow responds to fight off infections in the body.

Full description

PRIMARY OBJECTIVES:

I. Determine the cellular and mechanistic basis of bone marrow (BM) hematopoietic dysfunction in untreated MBL and CLL patients.

II. Determine if MBL and CLL B cell derived cellular products directly alter the differentiation and functional capacities of Hematopoietic Stem and Progenitor Cells (HSPCs).

III. Utilize the Emu-Tcl1 transgenic mouse model to determine how MBL and CLL patient-derived cellular products alter BM hematopoiesis.

OUTLINE: This is an observational study.

Patients undergo blood sample collection and bone marrow aspiration and biopsy and have their medical records reviewed on study.

Enrollment

50 estimated patients

Sex

All

Ages

40+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Subjects in the CLL cohort who are eligible for these studies will have a clinically established diagnosis of CLL as assessed by flow cytometry and will include subjects who
- Remain untreated
- Are currently being treated
- Who have already been treated
Subjects in the MBL cohort will have a clinically established diagnosis of MBL
Healthy age-matched control subjects
Healthy younger control subjects aged > 40 years